Drugs / WX-037
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01859351 | Jul 2013 → Apr 2014 | cancer | Heidelberg Pharma AG | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WX-037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01859351 ↗ |
| Known as | UCB1370037 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545385 ↗ |
| Action | Inhibit | “the novel PI3K inhibitor WX-037” NCT01859351 ↗ |